{"id":30426,"date":"2017-05-29T16:54:17","date_gmt":"2017-05-29T15:54:17","guid":{"rendered":"http:\/\/blog.cofb.cat\/?p=30426"},"modified":"2017-05-29T16:54:17","modified_gmt":"2017-05-29T15:54:17","slug":"eines-pel-seguiment-del-pacient-renal-des-de-la-farmacia-comunitaria","status":"publish","type":"post","link":"https:\/\/www.cofb.org\/ca\/2017\/05\/29\/eines-pel-seguiment-del-pacient-renal-des-de-la-farmacia-comunitaria\/","title":{"rendered":"Eines pel seguiment del pacient renal des de la farm\u00e0cia comunit\u00e0ria"},"content":{"rendered":"<p>El passat mes de maig,\u00a0 <strong>Alberto Mart\u00ednez-Castelao<\/strong>, metge especialista de l\u2019Hospital de Bellvitge, <strong>Pere Trav\u00e9<\/strong>, especialista en Bioqu\u00edmica Cl\u00ednica, i les farmac\u00e8utiques <strong>Marian March<\/strong> i<strong> Dra. M. \u00c0ngels V\u00eda<\/strong>, van presentar la \u201c<b>Guia consensuada per l\u2019ajust de dosi de medicaments en pacients amb insufici\u00e8ncia renal<\/b>\u201d, consensuada entre el Grup de Farm\u00e0cia Pr\u00e0ctica de la Universitat de Barcelona i la <a href=\"http:\/\/www.sen.es\/\" target=\"_blank\" rel=\"noopener\">Societat Espanyola de Nefrologia (<\/a>S.E.N.) en un acte que va acollir el COFB, moderat per la vocal de la Junta del Col\u00b7legi i responsable de la Comissi\u00f3 Delegada de Formaci\u00f3,<strong> Aina Surroca.<\/strong> Els responsables d\u2019aquest document van presentar la problem\u00e0tica de la malaltia renal i van mostrar les accions dutes a terme en els darrers anys des de la S.E.N. per tal d\u2019avan\u00e7ar en el cribratge i detecci\u00f3 de la malaltia. \u201cLa sessi\u00f3 tamb\u00e9 va permetre adquirir les habilitats pel seu \u00fas en les activitats farmac\u00e8utiques orientades a la implementaci\u00f3 de serveis farmac\u00e8utics relacionats amb l\u2019\u00fas segur dels medicaments\u201d explica Surroca.<\/p>\n<figure id=\"attachment_30435\" aria-describedby=\"caption-attachment-30435\" style=\"width: 610px\" class=\"wp-caption aligncenter\"><a href=\"http:\/\/blog.cofb.cat\/wp-content\/uploads\/2017\/05\/guia-insuficiencia-renal-COFB-4.jpg\"><img fetchpriority=\"high\" decoding=\"async\" class=\" wp-image-30435     \" alt=\"guia-insuficiencia renal COFB (4)\" src=\"http:\/\/blog.cofb.cat\/wp-content\/uploads\/2017\/05\/guia-insuficiencia-renal-COFB-4.jpg\" width=\"610\" height=\"257\" \/><\/a><figcaption id=\"caption-attachment-30435\" class=\"wp-caption-text\">D&#8217;esquerra a dreta: M. \u00c0ngels Via, Marian March, Aina Surroca, Pere Trav\u00e9 i Alberto Mart\u00ednez-Castelao<\/figcaption><\/figure>\n<div class=\"box shadow\"> <strong>La funci\u00f3 assistencial del farmac\u00e8utic est\u00e0 dirigida<\/strong>, entre altres aspectes, a <strong>evitar o limitar els potencials efectes nefrot\u00f2xics que tenen determinats medicaments.<\/strong> Les principals precaucions per evitar l&#8217;aparici\u00f3 aquests efectes nefrot\u00f2xics s\u00f3n:<\/p>\n<ul>\n<li>Con\u00e8ixer quins f\u00e0rmacs s\u00f3n nefrot\u00f2xics i el tipus de nefropatia que produeixen, a fi de poder identificar r\u00e0pidament els s\u00edmptomes caracter\u00edstics.<\/li>\n<li>Valorar si existeix un altre f\u00e0rmac de similar efic\u00e0cia, amb menor risc de nefrotoxicitat.<\/li>\n<li>Identificar i corregir, si \u00e9s possible, els factors de risc que faciliten l&#8217;aparici\u00f3 de nefrotoxicitat indu\u00efda per f\u00e0rmacs<\/li>\n<li>Si \u00e9s necessari emprar un f\u00e0rmac amb potencial nefrot\u00f2xic, realitzar controls peri\u00f2dics de la funci\u00f3 renal.<\/li>\n<li>Ajustar les dosis del f\u00e0rmac segons la taxa de filtraci\u00f3 glomerular per evitar la seva acumulaci\u00f3: reduir la dosi o perllongar l&#8217;interval interdosis.<\/li>\n<li>A m\u00e9s, tamb\u00e9 \u00e9s important la funci\u00f3 del farmac\u00e8utic per evitar o reduir els efectes potencials que la insufici\u00e8ncia renal pot produir sobre la farmacocin\u00e8tica dels medicaments que pugui estar utilitzant o vagi a utilitzar el pacient.<\/li>\n<\/ul>\n<p>Font: <a href=\"http:\/\/www.portalfarma.com\/Profesionales\/consejoinforma\/Paginas\/El-farmaceutico-crucial-en-prevencion-enfermedad-renal.aspx\" target=\"_blank\" rel=\"noopener\">Portalfarma <\/a><\/div>\n<figure id=\"attachment_30432\" aria-describedby=\"caption-attachment-30432\" style=\"width: 268px\" class=\"wp-caption alignleft\"><a href=\"http:\/\/blog.cofb.cat\/wp-content\/uploads\/2017\/05\/guia-insuficiencia-renal-COFB-1.jpg\"><img decoding=\"async\" class=\" wp-image-30432   \" alt=\"guia-insuficiencia renal COFB (1)\" src=\"http:\/\/blog.cofb.cat\/wp-content\/uploads\/2017\/05\/guia-insuficiencia-renal-COFB-1.jpg\" width=\"268\" height=\"179\" \/><\/a><figcaption id=\"caption-attachment-30432\" class=\"wp-caption-text\">Aina Surroca<\/figcaption><\/figure>\n<figure id=\"attachment_30434\" aria-describedby=\"caption-attachment-30434\" style=\"width: 268px\" class=\"wp-caption alignright\"><a href=\"http:\/\/blog.cofb.cat\/wp-content\/uploads\/2017\/05\/guia-insuficiencia-renal-COFB-3.jpg\"><img decoding=\"async\" class=\" wp-image-30434    \" alt=\"guia-insuficiencia renal COFB (3)\" src=\"http:\/\/blog.cofb.cat\/wp-content\/uploads\/2017\/05\/guia-insuficiencia-renal-COFB-3.jpg\" width=\"268\" height=\"179\" \/><\/a><figcaption id=\"caption-attachment-30434\" class=\"wp-caption-text\">Pere Trav\u00e9<\/figcaption><\/figure>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p><strong>Informaci\u00f3 relacionada, publicada pr\u00e8viament al Blog:<\/strong><\/p>\n<ul>\n<li><a href=\"http:\/\/blog.cofb.cat\/seguiment-del-pacient-diabetic-tipus-ii-a-la-farmacia-comunitaria\/\" target=\"_blank\" rel=\"noopener\">Seguiment del pacient diab\u00e8tic tipus II a la farm\u00e0cia comunit\u00e0ria<\/a><\/li>\n<li><a href=\"http:\/\/blog.cofb.cat\/atencio-farmaceutica-en-insuficiencia-renal\/\" target=\"_blank\" rel=\"noopener\">Atenci\u00f3 farmac\u00e8utica en insufici\u00e8ncia renal<\/a><\/li>\n<li><a href=\"http:\/\/blog.cofb.cat\/insuficiencia-renal-associada-a-vih-un-dels-temes-del-nou-numero-de-circular-farmaceutica\/\" target=\"_blank\" rel=\"noopener\">L\u2019eliminaci\u00f3 del xarampi\u00f3, farmacoter\u00e0pia i m\u00e9s al nou n\u00famero de Circular Farmac\u00e8utica (1er trimestre 2014) <\/a>&#8211; Farmassist\u00e8ncia: Insufici\u00e8ncia renal associada a VIH<\/li>\n<li><a href=\"http:\/\/blog.cofb.cat\/els-farmaceutics-aprenen-a-controlar-pacients-polimedicats-amb-insuficiencia-renal\/\" target=\"_blank\" rel=\"noopener\">Els farmac\u00e8utics aprenen a controlar pacients polimedicats amb insufici\u00e8ncia renal<\/a><\/li>\n<\/ul>\n<p><strong>Potser tamb\u00e9 t&#8217;interessa:<\/strong><\/p>\n<p><strong><a href=\"http:\/\/www.ub.edu\/medicamentoseninsuficienciarenal\/\" target=\"_blank\" rel=\"noopener\">Acc\u00e9s a la Guia,<\/a> via UB<\/strong><\/p>\n<p><a href=\"http:\/\/www.portalfarma.com\/Profesionales\/consejoinforma\/Paginas\/El-farmaceutico-crucial-en-prevencion-enfermedad-renal.aspx\" target=\"_blank\" rel=\"noopener\">El farmac\u00e9utico crucial en la prevenci\u00f3n de la enfermedad renal <\/a>(via Portalfarma)<br \/>\n<a href=\"http:\/\/medicaments.gencat.cat\/ca\/ciutadania\/informacio-i-consells\/persones-i-medicaments\/insuficiencia-renal\/\" target=\"_blank\" rel=\"noopener\">Insufici\u00e8ncia renal<\/a> (via Departament de Salut)<\/p>\n","protected":false},"excerpt":{"rendered":"<p>El passat mes de maig,\u00a0 Alberto Mart\u00ednez-Castelao, metge especialista de l\u2019Hospital de Bellvitge, Pere Trav\u00e9, especialista en Bioqu\u00edmica Cl\u00ednica, i les farmac\u00e8utiques Marian March i Dra. M. \u00c0ngels V\u00eda, van presentar la \u201cGuia consensuada per l\u2019ajust de dosi de medicaments en pacients amb insufici\u00e8ncia renal\u201d, consensuada entre el Grup de [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":30433,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_uag_custom_page_level_css":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"disabled","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[57],"tags":[2787,69,2788,70,2789,2197,2790,45,2791],"class_list":["post-30426","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-mon-collegial","tag-efectes-nefrotoxics","tag-farmacia-comunitaria","tag-farmacocinetica","tag-formacio","tag-funcio-renal","tag-insuficiencia-renal","tag-malaltia-renal","tag-medicaments","tag-nefrotoxicitat"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.4 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Eines pel seguiment del pacient renal des de la farm\u00e0cia comunit\u00e0ria<\/title>\n<meta name=\"description\" content=\"Eines pel seguiment del pacient renal des de la farm\u00e0cia comunit\u00e0ria\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/novaorg.cofb.net\/2017\/05\/29\/eines-pel-seguiment-del-pacient-renal-des-de-la-farmacia-comunitaria\/\" \/>\n<meta property=\"og:locale\" content=\"ca_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Eines pel seguiment del pacient renal des de la farm\u00e0cia comunit\u00e0ria\" \/>\n<meta property=\"og:description\" content=\"Eines pel seguiment del pacient renal des de la farm\u00e0cia comunit\u00e0ria\" \/>\n<meta property=\"og:url\" content=\"https:\/\/novaorg.cofb.net\/2017\/05\/29\/eines-pel-seguiment-del-pacient-renal-des-de-la-farmacia-comunitaria\/\" \/>\n<meta property=\"og:site_name\" content=\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/farmaceuticsbcn\/\" \/>\n<meta property=\"article:published_time\" content=\"2017-05-29T15:54:17+00:00\" \/>\n<meta name=\"author\" content=\"wpAdminCofbOrg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@farmaceuticsbcn\" \/>\n<meta name=\"twitter:site\" content=\"@farmaceuticsbcn\" \/>\n<meta name=\"twitter:label1\" content=\"Escrit per\" \/>\n\t<meta name=\"twitter:data1\" content=\"wpAdminCofbOrg\" \/>\n\t<meta name=\"twitter:label2\" content=\"Temps estimat de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minuts\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/novaorg.cofb.net\/2017\/05\/29\/eines-pel-seguiment-del-pacient-renal-des-de-la-farmacia-comunitaria\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2017\/05\/29\/eines-pel-seguiment-del-pacient-renal-des-de-la-farmacia-comunitaria\/\"},\"author\":{\"name\":\"wpAdminCofbOrg\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/person\/22ed7eea88da74b0fa4d3154ad87ffcb\"},\"headline\":\"Eines pel seguiment del pacient renal des de la farm\u00e0cia comunit\u00e0ria\",\"datePublished\":\"2017-05-29T15:54:17+00:00\",\"dateModified\":\"2017-05-29T15:54:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2017\/05\/29\/eines-pel-seguiment-del-pacient-renal-des-de-la-farmacia-comunitaria\/\"},\"wordCount\":533,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.cofb.org\/#organization\"},\"image\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2017\/05\/29\/eines-pel-seguiment-del-pacient-renal-des-de-la-farmacia-comunitaria\/#primaryimage\"},\"thumbnailUrl\":\"\",\"keywords\":[\"efectes nefrot\u00f2xics\",\"farm\u00e0cia comunit\u00e0ria\",\"farmacocin\u00e9tica\",\"Formaci\u00f3\",\"funci\u00f3 renal\",\"insufici\u00e8ncia renal\",\"malaltia renal\",\"medicaments\",\"nefrotoxicitat\"],\"articleSection\":[\"M\u00f3n col\u00b7legial\"],\"inLanguage\":\"ca\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/novaorg.cofb.net\/2017\/05\/29\/eines-pel-seguiment-del-pacient-renal-des-de-la-farmacia-comunitaria\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/novaorg.cofb.net\/2017\/05\/29\/eines-pel-seguiment-del-pacient-renal-des-de-la-farmacia-comunitaria\/\",\"url\":\"https:\/\/novaorg.cofb.net\/2017\/05\/29\/eines-pel-seguiment-del-pacient-renal-des-de-la-farmacia-comunitaria\/\",\"name\":\"Eines pel seguiment del pacient renal des de la farm\u00e0cia comunit\u00e0ria\",\"isPartOf\":{\"@id\":\"https:\/\/www.cofb.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2017\/05\/29\/eines-pel-seguiment-del-pacient-renal-des-de-la-farmacia-comunitaria\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2017\/05\/29\/eines-pel-seguiment-del-pacient-renal-des-de-la-farmacia-comunitaria\/#primaryimage\"},\"thumbnailUrl\":\"\",\"datePublished\":\"2017-05-29T15:54:17+00:00\",\"dateModified\":\"2017-05-29T15:54:17+00:00\",\"description\":\"Eines pel seguiment del pacient renal des de la farm\u00e0cia comunit\u00e0ria\",\"breadcrumb\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2017\/05\/29\/eines-pel-seguiment-del-pacient-renal-des-de-la-farmacia-comunitaria\/#breadcrumb\"},\"inLanguage\":\"ca\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/novaorg.cofb.net\/2017\/05\/29\/eines-pel-seguiment-del-pacient-renal-des-de-la-farmacia-comunitaria\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\/\/novaorg.cofb.net\/2017\/05\/29\/eines-pel-seguiment-del-pacient-renal-des-de-la-farmacia-comunitaria\/#primaryimage\",\"url\":\"\",\"contentUrl\":\"\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/novaorg.cofb.net\/2017\/05\/29\/eines-pel-seguiment-del-pacient-renal-des-de-la-farmacia-comunitaria\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Inici\",\"item\":\"https:\/\/novaorg.cofb.net\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Eines pel seguiment del pacient renal des de la farm\u00e0cia comunit\u00e0ria\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.cofb.org\/#website\",\"url\":\"https:\/\/www.cofb.org\/\",\"name\":\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.cofb.org\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.cofb.org\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"ca\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.cofb.org\/#organization\",\"name\":\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"url\":\"https:\/\/www.cofb.org\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png\",\"contentUrl\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png\",\"width\":500,\"height\":105,\"caption\":\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\"},\"image\":{\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/farmaceuticsbcn\/\",\"https:\/\/twitter.com\/farmaceuticsbcn\",\"https:\/\/www.instagram.com\/farmaceuticsbcn\/\",\"https:\/\/www.linkedin.com\/company\/farmaceuticsbcn\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/person\/22ed7eea88da74b0fa4d3154ad87ffcb\",\"name\":\"wpAdminCofbOrg\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/1721b20b3b8ca882c3b56ec6c978c594fff670e40c0718e9190eaeeb76aae7d8?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/1721b20b3b8ca882c3b56ec6c978c594fff670e40c0718e9190eaeeb76aae7d8?s=96&d=mm&r=g\",\"caption\":\"wpAdminCofbOrg\"},\"sameAs\":[\"http:\/\/192.168.64.122\/wordpress\"],\"url\":\"https:\/\/www.cofb.org\/ca\/author\/wpadmincofborg\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Eines pel seguiment del pacient renal des de la farm\u00e0cia comunit\u00e0ria","description":"Eines pel seguiment del pacient renal des de la farm\u00e0cia comunit\u00e0ria","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/novaorg.cofb.net\/2017\/05\/29\/eines-pel-seguiment-del-pacient-renal-des-de-la-farmacia-comunitaria\/","og_locale":"ca_ES","og_type":"article","og_title":"Eines pel seguiment del pacient renal des de la farm\u00e0cia comunit\u00e0ria","og_description":"Eines pel seguiment del pacient renal des de la farm\u00e0cia comunit\u00e0ria","og_url":"https:\/\/novaorg.cofb.net\/2017\/05\/29\/eines-pel-seguiment-del-pacient-renal-des-de-la-farmacia-comunitaria\/","og_site_name":"Col\u00b7legi de Farmac\u00e8utics de Barcelona","article_publisher":"https:\/\/www.facebook.com\/farmaceuticsbcn\/","article_published_time":"2017-05-29T15:54:17+00:00","author":"wpAdminCofbOrg","twitter_card":"summary_large_image","twitter_creator":"@farmaceuticsbcn","twitter_site":"@farmaceuticsbcn","twitter_misc":{"Escrit per":"wpAdminCofbOrg","Temps estimat de lectura":"3 minuts"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/novaorg.cofb.net\/2017\/05\/29\/eines-pel-seguiment-del-pacient-renal-des-de-la-farmacia-comunitaria\/#article","isPartOf":{"@id":"https:\/\/novaorg.cofb.net\/2017\/05\/29\/eines-pel-seguiment-del-pacient-renal-des-de-la-farmacia-comunitaria\/"},"author":{"name":"wpAdminCofbOrg","@id":"https:\/\/www.cofb.org\/#\/schema\/person\/22ed7eea88da74b0fa4d3154ad87ffcb"},"headline":"Eines pel seguiment del pacient renal des de la farm\u00e0cia comunit\u00e0ria","datePublished":"2017-05-29T15:54:17+00:00","dateModified":"2017-05-29T15:54:17+00:00","mainEntityOfPage":{"@id":"https:\/\/novaorg.cofb.net\/2017\/05\/29\/eines-pel-seguiment-del-pacient-renal-des-de-la-farmacia-comunitaria\/"},"wordCount":533,"commentCount":0,"publisher":{"@id":"https:\/\/www.cofb.org\/#organization"},"image":{"@id":"https:\/\/novaorg.cofb.net\/2017\/05\/29\/eines-pel-seguiment-del-pacient-renal-des-de-la-farmacia-comunitaria\/#primaryimage"},"thumbnailUrl":"","keywords":["efectes nefrot\u00f2xics","farm\u00e0cia comunit\u00e0ria","farmacocin\u00e9tica","Formaci\u00f3","funci\u00f3 renal","insufici\u00e8ncia renal","malaltia renal","medicaments","nefrotoxicitat"],"articleSection":["M\u00f3n col\u00b7legial"],"inLanguage":"ca","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/novaorg.cofb.net\/2017\/05\/29\/eines-pel-seguiment-del-pacient-renal-des-de-la-farmacia-comunitaria\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/novaorg.cofb.net\/2017\/05\/29\/eines-pel-seguiment-del-pacient-renal-des-de-la-farmacia-comunitaria\/","url":"https:\/\/novaorg.cofb.net\/2017\/05\/29\/eines-pel-seguiment-del-pacient-renal-des-de-la-farmacia-comunitaria\/","name":"Eines pel seguiment del pacient renal des de la farm\u00e0cia comunit\u00e0ria","isPartOf":{"@id":"https:\/\/www.cofb.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/novaorg.cofb.net\/2017\/05\/29\/eines-pel-seguiment-del-pacient-renal-des-de-la-farmacia-comunitaria\/#primaryimage"},"image":{"@id":"https:\/\/novaorg.cofb.net\/2017\/05\/29\/eines-pel-seguiment-del-pacient-renal-des-de-la-farmacia-comunitaria\/#primaryimage"},"thumbnailUrl":"","datePublished":"2017-05-29T15:54:17+00:00","dateModified":"2017-05-29T15:54:17+00:00","description":"Eines pel seguiment del pacient renal des de la farm\u00e0cia comunit\u00e0ria","breadcrumb":{"@id":"https:\/\/novaorg.cofb.net\/2017\/05\/29\/eines-pel-seguiment-del-pacient-renal-des-de-la-farmacia-comunitaria\/#breadcrumb"},"inLanguage":"ca","potentialAction":[{"@type":"ReadAction","target":["https:\/\/novaorg.cofb.net\/2017\/05\/29\/eines-pel-seguiment-del-pacient-renal-des-de-la-farmacia-comunitaria\/"]}]},{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/novaorg.cofb.net\/2017\/05\/29\/eines-pel-seguiment-del-pacient-renal-des-de-la-farmacia-comunitaria\/#primaryimage","url":"","contentUrl":""},{"@type":"BreadcrumbList","@id":"https:\/\/novaorg.cofb.net\/2017\/05\/29\/eines-pel-seguiment-del-pacient-renal-des-de-la-farmacia-comunitaria\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Inici","item":"https:\/\/novaorg.cofb.net\/"},{"@type":"ListItem","position":2,"name":"Eines pel seguiment del pacient renal des de la farm\u00e0cia comunit\u00e0ria"}]},{"@type":"WebSite","@id":"https:\/\/www.cofb.org\/#website","url":"https:\/\/www.cofb.org\/","name":"Col\u00b7legi de Farmac\u00e8utics de Barcelona","description":"","publisher":{"@id":"https:\/\/www.cofb.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.cofb.org\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"ca"},{"@type":"Organization","@id":"https:\/\/www.cofb.org\/#organization","name":"Col\u00b7legi de Farmac\u00e8utics de Barcelona","url":"https:\/\/www.cofb.org\/","logo":{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/","url":"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png","contentUrl":"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png","width":500,"height":105,"caption":"Col\u00b7legi de Farmac\u00e8utics de Barcelona"},"image":{"@id":"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/farmaceuticsbcn\/","https:\/\/twitter.com\/farmaceuticsbcn","https:\/\/www.instagram.com\/farmaceuticsbcn\/","https:\/\/www.linkedin.com\/company\/farmaceuticsbcn\/"]},{"@type":"Person","@id":"https:\/\/www.cofb.org\/#\/schema\/person\/22ed7eea88da74b0fa4d3154ad87ffcb","name":"wpAdminCofbOrg","image":{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/www.cofb.org\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/1721b20b3b8ca882c3b56ec6c978c594fff670e40c0718e9190eaeeb76aae7d8?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/1721b20b3b8ca882c3b56ec6c978c594fff670e40c0718e9190eaeeb76aae7d8?s=96&d=mm&r=g","caption":"wpAdminCofbOrg"},"sameAs":["http:\/\/192.168.64.122\/wordpress"],"url":"https:\/\/www.cofb.org\/ca\/author\/wpadmincofborg\/"}]}},"uagb_featured_image_src":{"full":false,"thumbnail":false,"medium":false,"medium_large":false,"large":false,"1536x1536":false,"2048x2048":false,"trp-custom-language-flag":false},"uagb_author_info":{"display_name":"wpAdminCofbOrg","author_link":"https:\/\/www.cofb.org\/ca\/author\/wpadmincofborg\/"},"uagb_comment_info":0,"uagb_excerpt":"El passat mes de maig,\u00a0 Alberto Mart\u00ednez-Castelao, metge especialista de l\u2019Hospital de Bellvitge, Pere Trav\u00e9, especialista en Bioqu\u00edmica Cl\u00ednica, i les farmac\u00e8utiques Marian March i Dra. M. \u00c0ngels V\u00eda, van presentar la \u201cGuia consensuada per l\u2019ajust de dosi de medicaments en pacients amb insufici\u00e8ncia renal\u201d, consensuada entre el Grup de [&hellip;]","_links":{"self":[{"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/posts\/30426","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/comments?post=30426"}],"version-history":[{"count":0,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/posts\/30426\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/"}],"wp:attachment":[{"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/media?parent=30426"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/categories?post=30426"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/tags?post=30426"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}